Home → Research News → Ask-the-Expert Conferences: Research News → June 2008: Updates from the 2008 ASCO Annual Meeting → Research on Evista for osteoporosis, recurrence?

Research on Evista for osteoporosis, recurrence?

Page last modified on: August 20, 2008

Question from WRDS: I had breast cancer almost 4 years ago and have been on Arimidex for 3 1/2 years. I've developed osteoporosis due to Arimidex and Lupron injections for ovarian ablation. Has there been any research to prove the effectiveness of Evista to treat both the osteoporosis and to prevent a breast cancer recurrence in postmenopausal women who have completed the 5-year course of aromatase inhibitors?: Answer —Generosa Grana, M.D., F.A.C.P.: There is no data on Evista in the setting of breast cancer. The only data that is available, as we discussed earlier, is in women with osteoporosis and women at increased risk of breast cancer. So it is speculation to suggest that, after 5 years of an aromatase inhibitor, Evista will give you benefit in terms of recurrence. It is a drug that can be used to treat osteoporosis, but we clearly have more effective drugs in that setting. So I tend to dissuade my patients from Evista after tamoxifen use or aromatase inhibitor use because of the lack of data.

On Wednesday, June 18, 2008 our Ask-the-Expert Online Conference was called Updates from the 2008 ASCO Annual Meeting. Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answered your questions about the latest research advances on screening, treatment, side effects, and more.

The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.

Email Updates

Stay informed about current research, online events, and more.

Meet the Experts

Generosa Grana, M.D., F.A.C.P. is the director of the Cooper Cancer Institute and heads the division of hematology/medical oncology at Cooper University Hospital.

Carol Kaplan, M.D. is an assistant professor of clinical medicine in the Rena Rowan Breast Center at the Hospital of the University of Pennsylvania. Her work revolves around the clinical care of breast cancer patients, as well as teaching medical students and house staff.

Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.

Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003

View Mobile Site